© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Merck

FDA Approved stamp
FDA OKs Delstrigo and Pifeltro
Pharma CEOs Walk Into a Congressional Hearing to Defend High Prices
Switching to Merck’s Delstrigo Is Safe and Effective

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Islatravir Shows Double Potential

Merck’s experimental HIV drug proves effective and well tolerated

$7M HIV Initiative to Help Underserved People in the Southeast

These three grantees will launch programs thanks to the Merck Foundation’s “HIV Care Connect.”

The International AIDS Society Conference’s Most Vital Findings

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Merck’s Experimental HIV Drug Islatravir Proves Effective and Well Tolerated

This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.
Islatravir subdermal implant

Long-Lasting Islatravir PrEP Implant Could Protect Against HIV for a Year

Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.

Merck Files With FDA for Expanded Approval of Pifeltro and Delstrigo

An OK would add an indication for the use of these HIV medications among those switching from stable regimens.

2018 Top HIV Treatment Stories

Here are the HIV treatment news stories with the most views this year.

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Treatment: Merck’s Doravirine

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Zepatier Zaps Acute Hep C in 8 Weeks

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

Picking Up the Pieces

The Impact of Hurricane Maria on HIV

FDA Approves Merck’s Delstrigo and Pifeltro to Treat HIV

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.

All the AIDS Conference News That’s Fit to Print

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Merck’s Experimental HIV Drug Doravirine Posts Promising 96-Week Results

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Zepatier Beats Almost All Acute Hepatitis C in Just 8 Weeks

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
Advertisement
Treatment News
Features